Spectrum Pharmaceuticals sees a rainbow of opportunities in its drug development pipeline. The drug firm, which focuses on anti-cancer therapies, markets injectable Fusilev for use with osteosarcoma patients; the drug reduces the toxic effects of a certain type of chemotherapy. Spectrum also sells Zevalin, a treatment for non-Hodgkin's lymphoma. In addition, the company has other oncology and urology therapeutic drug candidates in research and development stages, partially through licensing agreements or collaborative partnerships with other drugmakers.